Practice-Changing Study in Advanced Cervical Cancer
(MedPage Today) -- Adding pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) significantly slowed progression of metastatic cervical cancer and improved overall survival (OS), investigators in a randomized trial concluded...
Read more »